From Resistance to Remedy: the Role of Clustered Regularly Interspaced Short Palindromic Repeats System in Combating Antimicrobial Resistance-a Review

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 2024 Oct 15

PMID 39404843

Authors

Ali Raza

Pakiza Fatima

Bushra Yasmeen

Zulqarnain Amjad Rana

Doha El-Sayed Ellakwa

Affiliations

Soon will be listed here.

Abstract

The growing challenge of antimicrobial resistance (AMR) poses a significant and increasing risk to public health worldwide, necessitating innovative strategies to restore the efficacy of antibiotics. The precise genome-editing abilities of the CRISPR-Cas system have made it a potent instrument for directly targeting and eliminating antibiotic resistance genes. This review explored the mechanisms and applications of CRISPR-Cas systems in combating AMR. The latest developments in CRISPR technology have broadened its potential use, encompassing programmable antibacterial agents and improved diagnostic methods for antibiotic-resistant infections. Nevertheless, several challenges must be overcome for clinical success, including the survival of resistant bacteria, generation of anti-CRISPR proteins that reduce effectiveness, and genetic modifications that change target sequences. Additionally, the efficacy of CRISPR-Cas systems differs across bacterial species, making their universal application challenging. After overcoming these challenges, CRISPR-Cas has the potential to revolutionize AMR treatment, restore antibiotic efficacy, and reshape infection control.

References

Abadi S, Yan W, Amar D, Mayrose I . A machine learning approach for predicting CRISPR-Cas9 cleavage efficiencies and patterns underlying its mechanism of action. PLoS Comput Biol. 2017; 13(10):e1005807. PMC: 5658169. DOI: 10.1371/journal.pcbi.1005807. View

Adelman Z, Akbari O, Bauer J, Bier E, Bloss C, Carter S . Rules of the road for insect gene drive research and testing. Nat Biotechnol. 2017; 35(8):716-718. PMC: 5831321. DOI: 10.1038/nbt.3926. View

Allemailem K . Recent Advances in Understanding the Molecular Mechanisms of Multidrug Resistance and Novel Approaches of CRISPR/Cas9-Based Genome-Editing to Combat This Health Emergency. Int J Nanomedicine. 2024; 19:1125-1143. PMC: 10859101. DOI: 10.2147/IJN.S453566. View

Asadbeigi A, Norouzi M, Vafaei Sadi M, Saffari M, Bakhtiarizadeh M . CaSilico: A versatile CRISPR package for CRISPR RNA designing for Cas12, Cas13, and Cas14. Front Bioeng Biotechnol. 2022; 10:957131. PMC: 9395711. DOI: 10.3389/fbioe.2022.957131. View

Asmamaw M, Zawdie B . Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. Biologics. 2021; 15:353-361. PMC: 8388126. DOI: 10.2147/BTT.S326422. View

Barman N, Khan N, Islam M, Nain Z, Roy R, Haque A . CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease-A Narrative Review. Neurol Ther. 2020; 9(2):419-434. PMC: 7606404. DOI: 10.1007/s40120-020-00218-z. View

Basgall E, Goetting S, Goeckel M, Giersch R, Roggenkamp E, Schrock M . Gene drive inhibition by the anti-CRISPR proteins AcrIIA2 and AcrIIA4 in Saccharomyces cerevisiae. Microbiology (Reading). 2018; 164(4):464-474. PMC: 5982135. DOI: 10.1099/mic.0.000635. View

Bikard D, Barrangou R . Using CRISPR-Cas systems as antimicrobials. Curr Opin Microbiol. 2017; 37:155-160. DOI: 10.1016/j.mib.2017.08.005. View

Bikard D, Euler C, Jiang W, Nussenzweig P, Goldberg G, Duportet X . Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol. 2014; 32(11):1146-50. PMC: 4317352. DOI: 10.1038/nbt.3043. View

10.

Biswas A, Gagnon J, Brouns S, Fineran P, Brown C . CRISPRTarget: bioinformatic prediction and analysis of crRNA targets. RNA Biol. 2013; 10(5):817-27. PMC: 3737339. DOI: 10.4161/rna.24046. View

11.

Chang Q, Wang W, Regev-Yochay G, Lipsitch M, Hanage W . Antibiotics in agriculture and the risk to human health: how worried should we be?. Evol Appl. 2015; 8(3):240-7. PMC: 4380918. DOI: 10.1111/eva.12185. View

12.

Charpentier E . CRISPR-Cas9: how research on a bacterial RNA-guided mechanism opened new perspectives in biotechnology and biomedicine. EMBO Mol Med. 2015; 7(4):363-5. PMC: 4403038. DOI: 10.15252/emmm.201504847. View

13.

Chen S, Cao H, Xu Z, Huang J, Liu Z, Li T . A type I-F CRISPRi system unveils the novel role of CzcR in modulating multidrug resistance of . Microbiol Spectr. 2023; :e0112323. PMC: 10581170. DOI: 10.1128/spectrum.01123-23. View

14.

Chowdhury S, Carter J, Rollins M, Golden S, Jackson R, Hoffmann C . Structure Reveals Mechanisms of Viral Suppressors that Intercept a CRISPR RNA-Guided Surveillance Complex. Cell. 2017; 169(1):47-57.e11. PMC: 5478280. DOI: 10.1016/j.cell.2017.03.012. View

15.

Citorik R, Mimee M, Lu T . Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat Biotechnol. 2014; 32(11):1141-5. PMC: 4237163. DOI: 10.1038/nbt.3011. View

16.

Cui L, Bikard D . Consequences of Cas9 cleavage in the chromosome of Escherichia coli. Nucleic Acids Res. 2016; 44(9):4243-51. PMC: 4872102. DOI: 10.1093/nar/gkw223. View

17.

Davidson A, Lu W, Stanley S, Wang J, Mejdani M, Trost C . Anti-CRISPRs: Protein Inhibitors of CRISPR-Cas Systems. Annu Rev Biochem. 2020; 89:309-332. PMC: 9718424. DOI: 10.1146/annurev-biochem-011420-111224. View

18.

Dong H, Xiang H, Mu D, Wang D, Wang T . Exploiting a conjugative CRISPR/Cas9 system to eliminate plasmid harbouring the mcr-1 gene from Escherichia coli. Int J Antimicrob Agents. 2018; 53(1):1-8. DOI: 10.1016/j.ijantimicag.2018.09.017. View

19.

Duan C, Cao H, Zhang L, Xu Z . Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance. Front Microbiol. 2021; 12:716064. PMC: 8418092. DOI: 10.3389/fmicb.2021.716064. View

20.

Edgar R, Qimron U . The Escherichia coli CRISPR system protects from λ lysogenization, lysogens, and prophage induction. J Bacteriol. 2010; 192(23):6291-4. PMC: 2981215. DOI: 10.1128/JB.00644-10. View